Literature DB >> 15749877

Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal.

Florence Boisgérault1, Paloma Rueda, Cheng Ming Sun, Sandra Hervas-Stubbs, Marie Rojas, Claude Leclerc.   

Abstract

Controlling the cross-presentation of exogenous Ags to CD8+ T cells represents a major step for designing new vaccination strategies. Whereas several recombinant pseudo-viral particles have been used as delivery systems for triggering potent CTL responses to heterologous exogenous Ags, the adjuvant properties of virus-like particles (VLPs) themselves were little questioned. Here, we analyzed the contribution of the porcine parvovirus (PPV)-VLPs to the induction of protective cellular responses to exogenous Ags carried by an independent delivery system. Microspheres, which are known to transfer exogenous Ags into the MHC class I pathway, were chosen for delivering the immunodominant OVA(257-264) CD8+ T cell epitope (B-OVAp). This delivery system fulfills the requirements in terms of cross-presentation, but fails to induce cross-priming of specific CD8+ T cells. Coinjection of PPV-VLPs with B-OVAp results in the priming of potent CTL responses and type 1-biased immunity in a CD4- and CD40-independent manner, as efficiently as the recombinant PPV-VLPs carrying the same epitope (PPV-OVAp). Furthermore, vaccination with PPV-VLPs and B-OVAp was fully efficient to protect mice against the development of OVA-bearing melanoma. These findings indicate that PPV-VLPs act not only as a delivery system but also as a strong adjuvant when independently provided with exogenous Ag. Thus, dissociation between delivery system and adjuvant would provide a more flexible and reliable system to induce potent and protective CTL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749877     DOI: 10.4049/jimmunol.174.6.3432

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Authors:  Joseph M Thompson; Alan C Whitmore; Jennifer L Konopka; Martha L Collier; Erin M B Richmond; Nancy L Davis; Herman F Staats; Robert E Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

2.  Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation.

Authors:  Juliette Mouriès; Gabriel Moron; Géraldine Schlecht; Nicolas Escriou; Gilles Dadaglio; Claude Leclerc
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

3.  In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.

Authors:  Ana Villegas-Mendez; Marina I Garin; Estela Pineda-Molina; Eugenia Veratti; Juan A Bueren; Pascal Fender; Jean-Luc Lenormand
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

4.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

5.  Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.

Authors:  Elodie Belnoue; Paola Fontannaz-Bozzotti; Stéphane Grillet; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

6.  Conventional but not plasmacytoid dendritic cells foster the systemic virus-induced type I IFN response needed for efficient CD8 T cell priming.

Authors:  Sandra Hervas-Stubbs; Jose-Ignacio Riezu-Boj; Uxua Mancheño; Paloma Rueda; Lissette Lopez; Diego Alignani; Estefanía Rodríguez-García; Nathalie Thieblemont; Claude Leclerc
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

7.  Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors.

Authors:  Maxime Ferrand; Sylvie Da Rocha; Guillaume Corre; Anne Galy; Florence Boisgerault
Journal:  Mol Ther       Date:  2015-04-16       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.